BioCentury | Nov 18, 2020
Product Development

Nov. 17 Quick Takes: Phase III miss for BrainStorm’s ALS program; plus Novo, BioMarin-Deep Genomics, Lexicon, Seed-Lilly and RhoVac

...of Ozempic in the Phase IIIb SUSTAIN FORTE trial. The higher dose of the once-weekly GLP-1...
BioCentury | Nov 6, 2020
Deals

With $1.4B Emisphere buy, Novo gets delivery tech used in Rybelsus

...Danielsen told BioCentury that the pharma plans to apply the Eligen technology to more oral GLP-1...
...to $7.58 in afternoon trading Friday.Associate Editor Stephen Hansen contributed to this report.TARGETSGLP-1R (GLP1R) - Glucagon-like peptide-1...
BioCentury | Oct 16, 2020
Finance

VectivBio prepping pivotal GI trial with $110M crossover round that could presage IPO

A public listing could be VectivBio’s next financial step now that it has raised $110 million in a crossover round that will fund its planned Phase III trial in short bowel syndrome, as well as...
BioCentury | Sep 30, 2020
Distillery Therapeutics

An FGF21, GLP-1 fusion protein for diabetes, obesity

...By Claire Quang, Staff Writer DISEASE CATEGORY: Endocrine/metabolicINDICATION: Diabetes; obesityA fusion protein comprising FGF21 and GLP-1...
...gain and HbA1c levels compared with FGF21 or GLP-1 monotherapy.TARGET/MARKER/PATHWAY: Fibroblast growth factor 21 (FGF21); glucagon-like peptide-1 (GLP-1); glucagon-like peptide-1...
...Adv.; published online Aug. 26, 2020doi:10.1126/sciadv.aaz9890CONTACT: Ashutosh Chilkoti, Duke University, Durham, N.C.email: chilkoti@duke.edu Claire Quang Duke University Glucagon-like peptide-1 (GLP-1) Fibroblast...
BioCentury | Sep 30, 2020
Distillery Therapeutics

Endogenous bile acid identified for obesity and diabetes

...In HEK cells and a human colon cell line, cholic acid-7-sulfate activated GPBAR1 and induced GLP-1...
...inflammatory bowel disease and non-infectious diarrhea.TARGET/MARKER/PATHWAY: G protein-coupled bile acid receptor 1 (GPBAR1; TGR5); glucagon-like peptide-1 (GLP-1)EXPERIMENTAL...
BioCentury | Sep 30, 2020
Product Development

Partner Amgen becomes investor as Carmot pushes diabetes therapies ahead with $47M series C

...the mechanism of action of the natural GLP-1...
...– Gastric inhibitory polypeptide receptorGLP-1R (GLP1R) – Glucagon-like peptide-1...
...Martz Carmot Therapeutics Inc. Amgen Inc. KRAS proto-oncogene, GTPase (KRAS) (K-Ras) Glucagon-like peptide-1...
BioCentury | Sep 25, 2020
Product Development

Novo makes obesity pick as amylin/GLP-1 combo promises gastric bypass-like efficacy

...five obesity programs, Novo pins hopes on amylin/GLP-1...
...the company is focusing on the once-weekly GLP-1...
...and GLP-1 co-agonist. The latter is a glucagon/GLP-1/GIP...
BioCentury | Jul 10, 2020
Finance

How buysiders are sizing up commercial launches during the pandemic

...suggesting that their launched may hit harder. She noted that the launch of the oral GLP-1...
...Tumor necrosis factor receptor superfamily member 17 CGRP - Calcitonin gene-related peptide GLP-1 - Glucagon-like peptide-1...
BioCentury | Jun 19, 2020
Product Development

Hua shows sustained benefit in diabetics with glucokinase activator

...Lin said the 52-week data looked “better than any oral drug except for the oral GLP-1”...
...for depression, anxiety and Fragile X syndrome. Targets GCK (GK) - Glucokinase GLP-1 - Glucagon-like peptide-1 (GLP-1...
BioCentury | Jun 11, 2020
Deals

With $725M Corvidia takeout, Novo gets clinical atherosclerosis asset

...that although ziltivekimab is Novo Nordisk’s first dedicated clinical asset for atherosclerosis, it has tested GLP-1...
...“Nearing Threshold to Replace Gastric Bypass” ). Since FDA’s first approval of the subcutaneous GLP-1...
...as Rybelsus. Targets APOCII (APOC2) - Apolipoprotein C-II APOCIII (APOC3) - Apolipoprotein C-III GLP-1 - Glucagon-like peptide-1...
Items per page:
1 - 10 of 1317